Joseph Whitfield
Physician Assistant · Corpus Christi, TXNPI 1265495683
Payments from drug & device makers
Across 854 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Corium, LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$946
- plus $8K from 20 others
What the payments were for
- Food & beverage$16,95699%
- Education$1671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 169 | $2,463 |
| Alkermes, Inc. | 97 | $1,794 |
| Teva Pharmaceuticals USA, Inc. | 70 | $1,762 |
| Corium, LLC | 67 | $1,363 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $1,285 |
| Otsuka America Pharmaceutical, Inc. | 27 | $946 |
| Ironshore Pharmaceuticals Inc. | 40 | $930 |
| Neurocrine Biosciences, Inc. | 38 | $924 |
| Vanda Pharmaceuticals Inc. | 46 | $920 |
| AbbVie | 38 | $840 |
| Sunovion Pharmaceuticals Inc. | 58 | $797 |
| Johnson & Johnson | 25 | $561 |
| E.r. Squibb & Sons, L.L.C. | 16 | $450 |
| Indivior Inc. | 19 | $342 |
| Collegium Pharmaceutical, Inc. | 12 | $312 |
| Idorsia Pharmaceuticals US Inc | 25 | $309 |
| Tris Pharma Inc | 9 | $254 |
| Eisai Inc. | 19 | $238 |
| Lundbeck LLC | 12 | $229 |
| Axsome Therapeutics, Inc. | 9 | $142 |
| Acadia Pharmaceuticals Inc | 2 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Bausch Health US, LLC | 2 | $27 |
| Sage Therapeutics, LLC | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,309
- LYBALVI$892
- CAPLYTA$489
- VRAYLAR$355
- REXULTI$350
- JORNAY PM$343
- ARISTADA INITIO$327
- UZEDY$225
- Fanapt$125
- AUSTEDO$122
- COBENFY$121
- INGREZZA$118
- ZEPOSIA$116
- Dyanavel XR$115
- Quillivant$115
- Quillichew ER$115
- QELBREE$110
- ABILIFY MAINTENA$108
- ABILIFY ASIMTUFII$108
- Azstarys$102
How this compares
$17,123 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 47 | $337,596 |
| LybalviOlanzapine/Samidorphan Malate | 129 | $221,552 |
| Invega SustennaPaliperidone Palmitate | 54 | $174,313 |
| Austedo XrDeutetrabenazine | 30 | $167,399 |
| FanaptIloperidone | 62 | $137,553 |
| IngrezzaValbenazine Tosylate | 15 | $128,045 |
| PerserisRisperidone | 34 | $100,865 |
| VraylarCariprazine Hcl | 54 | $84,494 |
| CaplytaLumateperone Tosylate | 34 | $79,439 |
| UzedyRisperidone | 19 | $68,792 |
| RexultiBrexpiprazole | 38 | $57,859 |
| AptiomEslicarbazepine Acetate | 21 | $33,647 |
| Divalproex Sodium ErDivalproex Sodium | 367 | $31,912 |
| Clozapine | 103 | $21,220 |
| TrintellixVortioxetine Hydrobromide | 23 | $19,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $1,762 | $573,78896 claims |
| Alkermes, Inc.Lybalvi | $1,794 | $221,552129 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $561 | $183,77566 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $920 | $137,55362 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $924 | $128,04515 claims |
| Indivior Inc.Perseris | $342 | $100,86534 claims |
| AbbVieVraylar | $840 | $84,49454 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,285 | $79,43934 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $946 | $57,85938 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $797 | $33,64721 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $58 | $19,36823 claims |
| Axsome Therapeutics, Inc.Auvelity | $142 | $17,08913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Corpus Christi
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.